.gif)
Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, announced that it is launching a new suite of seven genetic testing panels for epilepsy.
Tests can be ordered from November 6 with the first samples expected to be tested on November 9.
Epilepsy is characterized by recurrent, unprovoked seizures. It is a common condition that affects about 1 in every 26 people, with approximately 150,000 new cases diagnosed in the US each year. Ambry’s new epilepsy tests include EpiFirst-Neonate, a targeted panel of genes most likely to cause neonatal seizures; EpiFirst-Fever, a targeted panel of genes most likely to cause febrile seizures; EpiFirst-IS, a targeted panel of genes most likely to cause infantile spasms; EpiFirst-Focal, a targeted panel of genes most likely to cause non-lesional focal epilepsy; PMEFirst, a targeted panel of genes most likely to cause progressive myoclonus epilepsy; PMENext, a broad panel of genes known to cause progressive myoclonus epilepsy; EpiNext, a broad panel of genes known to cause a variety of epilepsy syndromes.
Testing can begin with a targeted gene panel, and move to a broader panel if desired. Alternatively, the broadest panel could be ordered as the first test if appropriate for the clinical situation. This flexible model gives healthcare providers the ability to control and choose their testing approach to best suit their patient.
Subscribe to PharmaTutor News Alerts by Email >>
